Cyclacel Pharmaceuticals Inc (CYCCP NASDAQ) stock market data APIs
$5.673
0.26(4.6%)
as of July 7, 2025
Try our APIs with
free plan!
Cyclacel Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala Lumpur, Malaysia.
Prev. Close
5.673
Open
5.9318
High
6.3693
Low
5.4266
52 wk Range
3.1825-11.8519
Market Cap
10 686 K
Shares Outstanding
12 497 K
Revenue
14 000
EPS
-0.5377
Dividends (Yield)
0.1093
Beta
0.247
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cyclacel Pharmaceuticals Inc data using free add-ons & libraries
Get Cyclacel Pharmaceuticals Inc Fundamental Data
Cyclacel Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 14 000
- EBITDA: -12 679 500
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-09-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cyclacel Pharmaceuticals Inc News
New
Cyclacel Pharmaceuticals announces 1-for-15 reverse stock split
Cyclacel Pharmaceuticals (CYCC) announced that it expects to implement a 1-for-15 reverse stock split on its shares of common stock effective July 7, 2025, with trading to begin on a split-adjusted ba...
Cyclacel Pharmaceuticals Announces Stock Split
Cyclacel BERKELEY HEIGHTS, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company devel...
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
BERKELEY HEIGHTS, N.J., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
